Q3 2026 Highlights

VIATRIS™

Q3 2026 Financial Results


Total Revenues
$3.75B

Adjusted EBITDA*
$1.2B

Adjusted EPS*
$0.71

Free Cash Flow*
Ex. Transaction and Restructuring Costs
$895M

"Our third-quarter results reflect strong execution and reinforce our confidence in the growth trajectory of our business. Momentum across key areas of our base business, progress in our pipeline and the benefits of our enterprise-wide strategic review continue to strengthen our company. With the recent U.S. launch of Gwyn Lo™, approvals of Ryzumvi® in the U.S. and Wakix® in Japan, the potential upcoming approval and launch of fast-acting meloxicam and our recently announced agreement to acquire Pacira BioSciences, we are taking important steps to position Viatris for sustained revenue and earnings growth."



Delivering on Our 2026 Strategic Priorities

2026 Strategic Priorities	Execution
Deliver strong financial performance	• Q3 performance in line with our expectations, with flat total revenues, 1% adjusted EBITDA growth, and 3% adjusted EPS growth operationally
Drive commercial execution, including launches	• Received regulatory approval for Gwyn Lo™ in the U.S., Wakix® in Japan, and Ryzumvi® (presbyopia) in the U.S.
Advance our pipeline, including regulatory decisions for six product candidates	• Cenerimod SLE Phase 3 studies fully enrolled; Selatogrel Phase 3 enrollment on track for ~H1 2027 readout
Execute disciplined and balanced capital allocation	• Announced agreement to acquire Pacira BioSciences, advancing our innovative medicines strategy, which is expected to close in November 2026
Target accretive in-market business development	• Returned $717M of capital to shareholders YTD including $300M share repurchases and $417M dividends paid
Evolve our organization and modernize for future growth	• On track to deliver identified cost savings, while reinvesting in the business to support future growth

* Non-GAAP Financial Measure. For more information about Non-GAAP financial measures and reconciliations to the closest U.S. GAAP financial measure, as well as risks related to forward-looking statements, please read our Third-Quarter 2026 Financial Results press release on our website.

(1) Q3 2026 Free Cash Flow was $814M. Excluding the impact of transaction-related and restructuring-related costs of $81M, Q3 2026 Free Cash Flow was $895M.

© 2026 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris Company.

Viatris.com | LinkedIn | @ViatrisInc | @ViatrisInc | YouTube